KR20210013380A - Composition for preventing or treating atopic dermatitis comprising extracts of Artemisia capillaris, Cinnamomum cassia, Scutellaria baicalensis and Coptis japonica - Google Patents
Composition for preventing or treating atopic dermatitis comprising extracts of Artemisia capillaris, Cinnamomum cassia, Scutellaria baicalensis and Coptis japonica Download PDFInfo
- Publication number
- KR20210013380A KR20210013380A KR1020190089035A KR20190089035A KR20210013380A KR 20210013380 A KR20210013380 A KR 20210013380A KR 1020190089035 A KR1020190089035 A KR 1020190089035A KR 20190089035 A KR20190089035 A KR 20190089035A KR 20210013380 A KR20210013380 A KR 20210013380A
- Authority
- KR
- South Korea
- Prior art keywords
- atopic dermatitis
- preventing
- extract
- mixed extract
- cinnamon
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 75
- 239000000203 mixture Substances 0.000 title claims abstract description 47
- 206010012438 Dermatitis atopic Diseases 0.000 title claims abstract description 41
- 201000008937 atopic dermatitis Diseases 0.000 title claims abstract description 41
- 241000218203 Coptis japonica Species 0.000 title claims abstract description 17
- 241000092668 Artemisia capillaris Species 0.000 title claims abstract description 14
- 235000008658 Artemisia capillaris Nutrition 0.000 title claims abstract description 14
- 244000037364 Cinnamomum aromaticum Species 0.000 title claims abstract description 14
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 title claims abstract description 14
- 235000021511 Cinnamomum cassia Nutrition 0.000 title claims abstract description 14
- 240000004534 Scutellaria baicalensis Species 0.000 title claims abstract description 14
- 235000017089 Scutellaria baicalensis Nutrition 0.000 title claims abstract description 14
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 239000002537 cosmetic Substances 0.000 claims abstract description 13
- 230000003266 anti-allergic effect Effects 0.000 claims abstract description 12
- 230000003078 antioxidant effect Effects 0.000 claims abstract description 12
- 239000003963 antioxidant agent Substances 0.000 claims abstract description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 26
- 241000723347 Cinnamomum Species 0.000 claims description 23
- 235000017803 cinnamon Nutrition 0.000 claims description 23
- 239000004480 active ingredient Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 14
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 14
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 13
- 229910052737 gold Inorganic materials 0.000 claims description 13
- 239000010931 gold Substances 0.000 claims description 13
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 claims description 12
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims description 12
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims description 12
- 239000002904 solvent Substances 0.000 claims description 11
- 235000013402 health food Nutrition 0.000 claims description 10
- 230000037319 collagen production Effects 0.000 claims description 9
- 244000265736 Nelumbo pentapetala Species 0.000 claims description 8
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 8
- 230000002829 reductive effect Effects 0.000 claims description 8
- 230000001965 increasing effect Effects 0.000 claims description 7
- 102000012422 Collagen Type I Human genes 0.000 claims description 6
- 108010022452 Collagen Type I Proteins 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 230000002265 prevention Effects 0.000 claims description 5
- 239000011259 mixed solution Substances 0.000 claims description 4
- 230000000694 effects Effects 0.000 abstract description 11
- 108010035532 Collagen Proteins 0.000 abstract description 3
- 102000008186 Collagen Human genes 0.000 abstract description 3
- 229920001436 collagen Polymers 0.000 abstract description 3
- 235000013376 functional food Nutrition 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 20
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 16
- -1 cappillin Chemical compound 0.000 description 12
- 238000000605 extraction Methods 0.000 description 11
- 239000002609 medium Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 206010003645 Atopy Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 239000000047 product Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- 241000218202 Coptis Species 0.000 description 6
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 239000002158 endotoxin Substances 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000000546 pharmaceutical excipient Substances 0.000 description 6
- 239000000843 powder Substances 0.000 description 6
- 235000002991 Coptis groenlandica Nutrition 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 229920006008 lipopolysaccharide Polymers 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 241000037740 Coptis chinensis Species 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 3
- 238000008157 ELISA kit Methods 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- 208000024780 Urticaria Diseases 0.000 description 3
- 102000007478 beta-N-Acetylhexosaminidases Human genes 0.000 description 3
- 108010085377 beta-N-Acetylhexosaminidases Proteins 0.000 description 3
- 239000001913 cellulose Substances 0.000 description 3
- 235000010980 cellulose Nutrition 0.000 description 3
- 229920002678 cellulose Polymers 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013373 food additive Nutrition 0.000 description 3
- 239000002778 food additive Substances 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 239000003205 fragrance Substances 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000049 pigment Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000007921 spray Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000011782 vitamin Substances 0.000 description 3
- 235000013343 vitamin Nutrition 0.000 description 3
- 229940088594 vitamin Drugs 0.000 description 3
- 229930003231 vitamin Natural products 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 241000207923 Lamiaceae Species 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 239000007990 PIPES buffer Substances 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 241000218201 Ranunculaceae Species 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 230000001093 anti-cancer Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 239000000378 calcium silicate Substances 0.000 description 2
- 229910052918 calcium silicate Inorganic materials 0.000 description 2
- 235000012241 calcium silicate Nutrition 0.000 description 2
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 2
- NTKNGUAZSFAKEE-UHFFFAOYSA-N capillarisin Chemical compound C=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1OC1=CC=C(O)C=C1 NTKNGUAZSFAKEE-UHFFFAOYSA-N 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000005194 fractionation Methods 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 241000411851 herbal medicine Species 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000002075 main ingredient Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- GUAFOGOEJLSQBT-UHFFFAOYSA-N scoparone Chemical compound C1=CC(=O)OC2=C1C=C(OC)C(OC)=C2 GUAFOGOEJLSQBT-UHFFFAOYSA-N 0.000 description 2
- 239000000377 silicon dioxide Substances 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000000638 solvent extraction Methods 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000000341 volatile oil Substances 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 description 1
- DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 1
- YLRXAIKMLINXQY-ZDUSSCGKSA-O (S)-magnoflorine Chemical compound C1=C(OC)C(O)=C2C3=C(O)C(OC)=CC=C3C[C@@H]3[N+](C)(C)CCC1=C23 YLRXAIKMLINXQY-ZDUSSCGKSA-O 0.000 description 1
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 235000006491 Acacia senegal Nutrition 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 208000028185 Angioedema Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000208838 Asteraceae Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 241000723346 Cinnamomum camphora Species 0.000 description 1
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- XDVZNDLANFJOQR-UHFFFAOYSA-N Coptisine Natural products O=Cc1c2OCOc2ccc1C=C3/NCCc4cc5OCOc5cc34 XDVZNDLANFJOQR-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- GSFDOOHGKOHDEL-UHFFFAOYSA-N Dalpanitin Natural products COc1cc(ccc1O)C2=COc3c(C4OC(CO)C(O)C(O)C4O)c(O)cc(O)c3C2=O GSFDOOHGKOHDEL-UHFFFAOYSA-N 0.000 description 1
- 238000011891 EIA kit Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- MXTLAHSTUOXGQF-UHFFFAOYSA-O Jatrorrhizine Chemical compound COC1=CC=C2C=C3C(C=C(C(=C4)O)OC)=C4CC[N+]3=CC2=C1OC MXTLAHSTUOXGQF-UHFFFAOYSA-O 0.000 description 1
- ZCVMWBYGMWKGHF-UHFFFAOYSA-N Ketotifene Chemical compound C1CN(C)CCC1=C1C2=CC=CC=C2CC(=O)C2=C1C=CS2 ZCVMWBYGMWKGHF-UHFFFAOYSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- KYEAXNAYHSCLMT-CVVGWEDFSA-N Magnoflorine Natural products C[C@H]1OC=C2[C@@H]3[C@@H]1CN4CCc5c([nH]c6ccccc56)[C@@H]4[C@@H]3OC2=O KYEAXNAYHSCLMT-CVVGWEDFSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- NULAJYZBOLVQPQ-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine Chemical compound C1=CC=C2C(NCCN)=CC=CC2=C1 NULAJYZBOLVQPQ-UHFFFAOYSA-N 0.000 description 1
- MZNYWPRCVDMOJG-UHFFFAOYSA-N N-(1-naphthyl)ethylenediamine dihydrochloride Chemical compound [Cl-].[Cl-].C1=CC=C2C([NH2+]CC[NH3+])=CC=CC2=C1 MZNYWPRCVDMOJG-UHFFFAOYSA-N 0.000 description 1
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 1
- PTPHDVKWAYIFRX-UHFFFAOYSA-N Palmatine Natural products C1C2=C(OC)C(OC)=CC=C2C=C2N1CCC1=C2C=C(OC)C(OC)=C1 PTPHDVKWAYIFRX-UHFFFAOYSA-N 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 108010050808 Procollagen Proteins 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 230000002292 Radical scavenging effect Effects 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010040914 Skin reaction Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 206010045240 Type I hypersensitivity Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 1
- LCXREBMNASQAOC-UHFFFAOYSA-N Worenine Chemical compound C1=C2C(C)=C(C=3C(=CC=4OCOC=4C=3)CC3)[N+]3=CC2=CC2=C1OCO2 LCXREBMNASQAOC-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 230000002790 anti-mutagenic effect Effects 0.000 description 1
- 230000001166 anti-perspirative effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003213 antiperspirant Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000010216 atopic IgE responsiveness Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 1
- 229940015301 baicalein Drugs 0.000 description 1
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 1
- 229960003321 baicalin Drugs 0.000 description 1
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 1
- 229940093265 berberine Drugs 0.000 description 1
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229960000846 camphor Drugs 0.000 description 1
- 229930008380 camphor Natural products 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- ARQRPTNYUOLOGH-UHFFFAOYSA-N chcl3 chloroform Chemical compound ClC(Cl)Cl.ClC(Cl)Cl ARQRPTNYUOLOGH-UHFFFAOYSA-N 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- LUXPUVKJHVUJAV-UHFFFAOYSA-M coptisine, chloride Chemical compound [Cl-].C1=C2C=C(C3=C(C=C4OCOC4=C3)CC3)[N+]3=CC2=C2OCOC2=C1 LUXPUVKJHVUJAV-UHFFFAOYSA-M 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 229960000956 coumarin Drugs 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000007791 dehumidification Methods 0.000 description 1
- 239000003599 detergent Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 108010067755 dinitrophenyl-bovine serum albumin Proteins 0.000 description 1
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 229930003935 flavonoid Natural products 0.000 description 1
- 150000002215 flavonoids Chemical class 0.000 description 1
- 235000017173 flavonoids Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 229960002449 glycine Drugs 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000007233 immunological mechanism Effects 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 229960004958 ketotifen Drugs 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000017830 lymphoblastoma Diseases 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- WPHGSKGZRAQSGP-UHFFFAOYSA-N methylenecyclohexane Natural products C1CCCC2CC21 WPHGSKGZRAQSGP-UHFFFAOYSA-N 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940124641 pain reliever Drugs 0.000 description 1
- QUCQEUCGKKTEBI-UHFFFAOYSA-N palmatine Chemical compound COC1=CC=C2C=C(C3=C(C=C(C(=C3)OC)OC)CC3)[N+]3=CC2=C1OC QUCQEUCGKKTEBI-UHFFFAOYSA-N 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 230000008855 peristalsis Effects 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- SVHDRHWULLNMQC-UHFFFAOYSA-N scoparone Natural products C1=CC(=O)OC2=C1C=C(C(=O)C)C(C(C)=O)=C2 SVHDRHWULLNMQC-UHFFFAOYSA-N 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 238000010898 silica gel chromatography Methods 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 230000035483 skin reaction Effects 0.000 description 1
- 231100000430 skin reaction Toxicity 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 239000012089 stop solution Substances 0.000 description 1
- FDDDEECHVMSUSB-UHFFFAOYSA-N sulfanilamide Chemical compound NC1=CC=C(S(N)(=O)=O)C=C1 FDDDEECHVMSUSB-UHFFFAOYSA-N 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000001648 tannin Substances 0.000 description 1
- 235000018553 tannin Nutrition 0.000 description 1
- 229920001864 tannin Polymers 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 230000002227 vasoactive effect Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/282—Artemisia, e.g. wormwood or sagebrush
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/54—Lauraceae (Laurel family), e.g. cinnamon or sassafras
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/71—Ranunculaceae (Buttercup family), e.g. larkspur, hepatica, hydrastis, columbine or goldenseal
- A61K36/718—Coptis (goldthread)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
- A61K2800/5922—At least two compounds being classified in the same subclass of A61K8/18
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cosmetics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
본 발명은 인진(Artemisia capillaris), 계피(Cinnamomum cassia), 황금(Scutellaria baicalensis) 및 황련(Coptis japonica)의 혼합추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 약학 조성물, 아토피 피부염 예방 또는 개선용 화장료 조성물, 아토피 피부염 예방 또는 개선용 건강식품 조성물에 관한 것이다.The present invention is a pharmaceutical composition for the prevention or treatment of atopic dermatitis comprising a mixed extract of injin ( Artemisia capillaris ), cinnamon ( Cinnamomum cassia ), golden ( Scutellaria baicalensis ) and Coptis japonica as an active ingredient, for preventing or improving atopic dermatitis It relates to a cosmetic composition, a health food composition for preventing or improving atopic dermatitis.
아토피(atopy)는 그리스어로 '이상한' 혹은 '부적절한'이란 의미로, 음식 또는 물질에 대한 알레르기 반응이 유전적으로 발생하는 만성 알레르기성 염증 질환이다. 세계적으로 대두되고 있는 아토피 피부염(atopic dermatitis)은 만성 염증성 피부질환으로 세균, 바이러스 감염에 의해 더욱 악화되는 것으로 알려져 있다. 특히, 유소아기에 높은 발병을 나타내는 아토피 피부염은 최근 국내에서도 그 빈도가 점차 증가하고 있어 아토피 치료에 의한 경제적 손실도 높아지고 있다.Atopy means'weird' or'inappropriate' in Greek, and is a chronic allergic inflammatory disease in which allergic reactions to food or substances occur genetically. Atopic dermatitis, which is emerging worldwide, is a chronic inflammatory skin disease and is known to be exacerbated by bacterial and viral infections. In particular, the frequency of atopic dermatitis, which has a high onset in childhood and infancy, is gradually increasing in Korea in recent years, and thus economic losses due to atopic treatment are also increasing.
아토피 유발인자를 가지고 있는 사람은 집먼지, 진드기, 동물의 털, 음식물, 꽃가루, 곰팡이 등과 같이 외부환경에서 자주 접하는 단백물질에 대한 피부반응검사에서 흔히 두드러기 반응을 나타내며, 특정한 음식을 먹거나 흡입하게 되면 가려움증, 두드러기, 혈관부종, 재채기, 콧물, 코막힘, 결막충혈, 눈물 등의 증상을 나타낸다. 아토피 유발인자에 의한 알레르기 질환으로는 아토피성 피부염, 알레르기성 비염, 천식, 알레르기성 결막염, 알레르기성 장관염, 아토피성 두드러기 등이 있다. People with atopic inducing factors often exhibit a hives reaction in skin reaction tests to protein substances frequently encountered in the external environment such as house dust, mites, animal hair, food, pollen, and mold, and itching when eating or inhaling certain foods , Hives, angioedema, sneezing, runny nose, stuffy nose, conjunctival congestion, and tears. Allergic diseases caused by atopic triggers include atopic dermatitis, allergic rhinitis, asthma, allergic conjunctivitis, allergic enteritis, and atopic urticaria.
아토피 피부염의 병인은 아직까지 명확하게 규명되지는 않았으나 T 림프구의 활성화, 사이토카인 체계의 이상, 세포매개성 면역의 감소, IgE의 증가와 같은 면역학적 기전과 비만세포와 호염구에서 분비되는 히스타민에 의해 즉시형 과민반응과 소양감을 유발하는 혈관 작용성 매개체에 의한 것으로 알려져 있다. The etiology of atopic dermatitis has not yet been clearly identified, but it is caused by immunological mechanisms such as activation of T lymphocytes, abnormal cytokine system, decrease in cell-mediated immunity, increase in IgE, and histamine secreted from mast cells and basophils. It is known to be caused by a vasoactive mediator that causes immediate hypersensitivity reactions and itching.
최근 어린이는 물론 성인 아토피 피부염의 증가도 심각해지고 있으며, 심한 경우 취업, 결혼 등 사회생활에 지장을 초래하여 이는 심각한 사회적 문제로 대두되고 있다. 이러한 경우, 심하면 심각한 정신적 스트레스로 인한 대인기피 및 우울증이 유발되기도 한다. 이와 같이, 아토피 피부염이 심각한 사회적, 의학적 문제로 부각됨에도 불구하고 현재까지 효율적인 치료제가 부재한 실정이다.Recently, the increase of atopic dermatitis in adults as well as children is becoming more serious, and in severe cases, it causes a hindrance to social life such as employment and marriage, which has emerged as a serious social problem. In this case, severe mental stress can lead to extreme popularity and depression. As described above, although atopic dermatitis has emerged as a serious social and medical problem, there is no effective treatment to date.
국내 많은 연구진들이 아토피 피부염을 개선하기 위한 연구 및 제품화에 노력을 기울이고 있으나, 개발되는 제품의 대부분이 시장 진입 초기에 사라지는 현상이 반복되고 있다. 이러한 이유는 아토피 피부염이 유발되고 악화되는 병리학적 기전에 대응되는 제품의 개발보다는 막연히 피부의 보습 효과를 강화하거나 저자극성 화장품류들이 아토피 개선 제품으로 개발되고 있기 때문이다. 그러므로 시장 진출에 성공하기 위해서는 아토피 피부염을 유발시키거나 악화시키는 병리적 기전을 바탕으로 연구하여 제품을 개발해야 한다.Although many domestic researchers are making efforts to research and commercialize products to improve atopic dermatitis, the phenomenon that most of the developed products disappear at the beginning of market entry is repeating. This is because, rather than developing products that respond to the pathological mechanisms that cause and worsen atopic dermatitis, vaguely enhancing the moisturizing effect of the skin or hypoallergenic cosmetics are being developed as atopic improvement products. Therefore, in order to successfully enter the market, it is necessary to develop a product by researching based on the pathological mechanism that causes or worsens atopic dermatitis.
이에, 본 발명자들은 아토피 피부염에 대한 기능성 천연물 소재를 탐색하여 유용한 기능성을 갖는 아토피 피부염 치료제를 개발하고자 한다.Accordingly, the present inventors seek to develop a therapeutic agent for atopic dermatitis having useful functionality by searching for a functional natural material for atopic dermatitis.
본 발명의 목적은 아토피 피부염 예방 또는 치료용 약학 조성물을 제공하는 데에 있다.An object of the present invention is to provide a pharmaceutical composition for preventing or treating atopic dermatitis.
본 발명의 다른 목적은 아토피 피부염 예방 또는 개선용 화장료 조성물을 제공하는 데에 있다.Another object of the present invention is to provide a cosmetic composition for preventing or improving atopic dermatitis.
본 발명의 또 다른 목적은 아토피 피부염 예방 또는 개선용 건강식품 조성물을 제공하는 데에 있다.Another object of the present invention is to provide a health food composition for preventing or improving atopic dermatitis.
상기 목적을 달성하기 위하여, 본 발명은 인진(Artemisia capillaris), 계피(Cinnamomum cassia), 황금(Scutellaria baicalensis) 및 황련(Coptis japonica)의 혼합추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention is a pharmaceutical composition for the prevention or treatment of atopic dermatitis comprising a mixed extract of injin (Artemisia capillaris), cinnamon (Cinnamomum cassia), gold (Scutellaria baicalensis) and Coptis japonica as an active ingredient Provides.
또한, 본 발명은 인진(Artemisia capillaris), 계피(Cinnamomum cassia), 황금(Scutellaria baicalensis) 및 황련(Coptis japonica)의 혼합추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 개선용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for preventing or improving atopic dermatitis comprising a mixed extract of Injin (Artemisia capillaris), cinnamon (Cinnamomum cassia), Golden (Scutellaria baicalensis) and Coptis japonica as an active ingredient.
또한, 본 발명은 인진(Artemisia capillaris), 계피(Cinnamomum cassia), 황금(Scutellaria baicalensis) 및 황련(Coptis japonica)의 혼합추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 개선용 건강식품 조성물을 제공한다.In addition, the present invention provides a health food composition for preventing or improving atopic dermatitis comprising a mixed extract of Injin (Artemisia capillaris), cinnamon (Cinnamomum cassia), Golden (Scutellaria baicalensis) and Coptis japonica as an active ingredient.
또한, 본 발명은 인진, 계피, 황금 및 황련을 (1~10):(1~10):(1~10):(1~10)의 중량비로 혼합하여 혼합물을 제조하는 제 1단계; 상기 혼합물에 물, 탄소수 1 내지 4의 알코올 또는 이의 혼합용액으로부터 선택된 용매를 첨가하고, 40 내지 80℃의 온도에서 3 내지 5시간 동안 추출물을 추출하는 제 2단계; 및 상기 추출물을 진공 농축시키고, 감압 농축하는 제 3단계;를 포함하는 혼합추출물의 제조방법을 제공한다.In addition, the present invention is a first step of preparing a mixture by mixing injin, cinnamon, gold and yellow lotus in a weight ratio of (1-10):(1-10):(1-10):(1-10); A second step of adding a solvent selected from water, alcohol having 1 to 4 carbon atoms, or a mixed solution thereof to the mixture, and extracting the extract for 3 to 5 hours at a temperature of 40 to 80°C; And a third step of vacuum concentrating the extract and concentrating under reduced pressure.
본 발명에서는 인진, 계피, 황금 및 황련의 혼합추출물이 우수한 항염, 항알레르기, 항산화 및 손상된 피부를 복구하는 콜라겐 생성 증가 효능을 나타내는 것을 확인한 바, 상기와 같은 효능을 가지는 본 발명의 혼합추출물은 아토피 피부염 예방 또는 치료용 약학 조성물, 아토피 피부염 예방 또는 개선용 화장료 조성물, 아토피 피부염 예방 또는 개선용 건강식품 조성물 등으로 유용하게 활용될 수 있다. In the present invention, it was confirmed that the mixed extract of Injin, Cinnamon, Golden, and Coptis chinensis exhibited excellent anti-inflammatory, anti-allergic, antioxidant, and collagen production increasing efficacy for repairing damaged skin, and the mixed extract of the present invention having the above effects is atopic It can be usefully used as a pharmaceutical composition for preventing or treating dermatitis, a cosmetic composition for preventing or improving atopic dermatitis, a health food composition for preventing or improving atopic dermatitis, and the like.
도 1은 인진, 계피, 황금 및 황련을 이용하여 제조된 혼합추출물의 TNF-α 발현 억제 효과를 확인한 결과이다.
도 2는 인진, 계피, 황금 및 황련을 이용하여 제조된 혼합추출물의 IgE 발현 억제 효과를 확인한 결과다.
도 3은 인진, 계피, 황금 및 황련을 이용하여 제조된 혼합추출물의 Type I 콜라겐 생성능을 확인한 결과이다. 1 is a result of confirming the TNF-α expression inhibitory effect of a mixed extract prepared using Injin, Cinnamon, Golden, and Coptis.
2 is a result of confirming the effect of inhibiting IgE expression of a mixed extract prepared using Injin, Cinnamon, Golden, and Coptis.
3 is a result of confirming the ability to produce Type I collagen of a mixed extract prepared using Injin, Cinnamon, Golden, and Coptis.
본 발명의 발명자들은 아토피 피부염에 대한 기능성 천연물 소재 탐색을 위해 연구를 거듭한 결과, 유용한 기능성을 갖는 인진, 계피, 황련 및 황금을 선정하였고, 이들의 혼합추출물이 항염, 항알레르기, 항산화 및 피부 콜라겐 생성 증가 효과를 나타내는 바, 아토피 피부염 예방, 개선 내지 치료에 활용될 수 있음을 확인하며 본 발명을 완성하였다. The inventors of the present invention have repeatedly researched to search for functional natural materials for atopic dermatitis, and as a result of selecting Injin, Cinnamon, Yellow Lotus, and Gold, which have useful functions, the mixed extracts thereof are anti-inflammatory, anti-allergic, antioxidant and skin collagen. The present invention was completed by confirming that it can be used for prevention, improvement or treatment of atopic dermatitis, as it shows the effect of increasing production.
이에, 본 발명은 인진(Artemisia capillaris), 계피(Cinnamomum cassia), 황금(Scutellaria baicalensis) 및 황련(Coptis japonica)의 혼합추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 치료용 약학 조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition for preventing or treating atopic dermatitis comprising a mixed extract of Injin (Artemisia capillaris), Cinnamon (Cinnamomum cassia), Golden (Scutellaria baicalensis) and Coptis japonica as an active ingredient.
본 발명에서 용어 “인진(Artemisia capillaris)”은 국화과 쑥속에 속하는 다년생 초본형 낙엽관목으로, 그 특유의 향기와 약효로 인하여 전통적으로 민간에서 식용, 약용, 단방약으로 애용되어 왔다. 맛이 쓰고 찬 성질의 생약으로, 주요 성분으로는 스코파론(scoparone), 카필린(cappillin), 카필라리신(capillarisin) 및 쿠마린(coumarin) 등의 성분을 함유하고 있다. 약리작용으로는 간 손상 억제 작용, 항암 효과, 항산화 작용, 혈중 지질 감소 및 간기능 개선 효과, 항돌연변이 효과, 항균 효과 등이 알려져 있다.In the present invention, the term “injin ( Artemisia capillaris )” is a perennial herbaceous deciduous shrub belonging to the genus Asteraceae, and has been traditionally used as edible, medicinal, and herbal medicine in the private sector due to its unique fragrance and medicinal effect. It is a herbal medicine with a bitter taste and a cold nature, and contains ingredients such as scoparone, cappillin, capillarisin, and coumarin as the main ingredients. As a pharmacological action, it is known that it has an inhibitory effect on liver damage, an anticancer effect, an antioxidant effect, a decrease in blood lipids and an improvement in liver function, an antimutagenic effect, and an antibacterial effect.
본 발명에서 용어 “계피(Cinnamomum cassia)”는 녹나무과의 사철푸른 교목의 껍질로 중국의 남부나 월남 등지에서 자생한다. 계피에는 정유(계피 알데히드 75~90%, 신나밀 알데히드 등) 1~3.4%, 탄닌질 2~3%, 점액, 탄수화물 등이 함유되어 있는데 5~6년 자란 나무에서 정유 함량이 높은 것으로 알려져 있다. 계피는 예로부터 발한제, 해열제, 진통제뿐만 아니라 식료품의 향료 등 다양하게 사용되어 왔다. 또한, 장 연동 운동을 촉진하고 장내의 이상 발효를 억제하는 방부 효과가 있는 것으로 알려져 있다. In the present invention, the term " Cinnamomum cassia " refers to the bark of a green tree of the camphor family and grows wild in southern China or Vietnam. Cinnamon contains 1 to 3.4% of essential oils (75 to 90% of cinnamon aldehydes, cinnamyl aldehyde, etc.), 2 to 3% of tannins, mucus, and carbohydrates.It is known that the essential oil content is high in trees grown for 5 to 6 years. Cinnamon has been used in various ways such as antiperspirant, antipyretic, pain reliever, as well as flavoring for food. In addition, it is known to have an antiseptic effect that promotes intestinal peristalsis and inhibits abnormal fermentation in the intestine.
본 발명에서 용어 “황금(Scutellaria baicalensis)”은 꿀풀과(Labiatae)에 속한 다년생 본초인 황금을 의미하며, 특히 황금의 뿌리를 거피하여 건조한 것을 의미할 수 있으나, 황금의 뿌리, 줄기, 입, 꽃 또는 종자 등 부위에 제한되지 않는다. 황금에는 바이칼린(baicalin), 바이칼레인(baicalein) 및 우고닌(wogonin)과 같은 플라보노이드류가 많이 함유되어 있으며, 약리 작용으로는 제습열, 지혈 등의 효능이 있어 고혈압, 유행성 뇌척수막염의 치료에 사용되어 왔다. In the present invention, the term “golden ( Scutellaria baicalensis )” refers to gold, which is a perennial herb belonging to the Lamiaceae family (Labiatae), and in particular, it may mean dried by peeling the golden root, but the golden root, stem, mouth, and flower Or it is not limited to the part such as seeds. Gold contains a lot of flavonoids such as baicalin, baicalein, and wogonin, and its pharmacological effects include dehumidification heat and hemostasis, so it is used to treat hypertension and epidemic meningitis. Has been.
본 발명에서 용어 “황련(Coptis japonica)”은 깽깽이풀이라고도 불리우는 쌍떡잎식물 미나리아재비목 미나리아재비과의 상록 여러해살이풀이다. 황련은 한국, 일본 및 중국 등지에서 분포하는 것으로 알려져 있으며, 줄기와 땅속 줄기의 단면이 노란색인 것에서 황련이라는 이름이 유래되었다. 주용 성분으로는 베르베린(berberine), 매그노플로린(magnoflorine), 콥티신(coptisine), 워레닌(worenine), 팔마틴(palmatine), 야테오리진(jateorrhizine) 등이 알려져 있다. 황련은 예로부터 강장, 동맥경화, 병후쇠약 또는 중풍 등에 효능이 있는 것으로 알려져 있고, 항암 작용 및 항미생물 작용 등이 보고된 바 있다. In the present invention, the term “Hwangryun ( Coptis japonica )” is an evergreen perennial plant of the dicotyledonous plant, Buttercups, and Buttercups family, also called Kenggipul. Hwangryeon is known to be distributed in Korea, Japan, and China, and the name Hwangryeon is derived from the yellow cross section of the stem and subterranean stem. As main ingredients, berberine, magnoflorine, coptisine, worenine, palmatine, jateorrhizine, and the like are known. Coptis Coptis has been known to be effective in tonicity, arteriosclerosis, post-illness weakness or stroke from ancient times, and anticancer and antimicrobial effects have been reported.
본 발명에 따른 혼합추출물은 당업계에 공지된 추출 및 분리방법을 사용하여 천연으로부터 추출 및 분리하여 수득한 것을 사용할 수 있으며, 본 발명에서 정의된 "혼합추출물"은 적절한 용매를 이용하여 인진, 계피, 황금 및 황련으로부터 추출한 것이며, 예를 들어, 조추출물, 극성용매 가용 추출물 또는 비극성용매 가용 추출물을 모두 포함한다. 상기 혼합추출물을 추출하기 위한 적절한 용매로는 약학적으로 허용되는 유기용매라면 어느 것을 사용해도 무방하며, 물 또는 유기용매를 사용할 수 있으며, 이에 제한되지는 않으나, 예를 들어, 정제수, 메탄올(methanol), 에탄올(ethanol), 프로판올(propanol), 이소프로판올(isopropanol), 부탄올(butanol) 등을 포함하는 탄소수 1 내지 4의 알코올, 아세톤(acetone), 에테르(ether), 벤젠(benzene), 클로로포름(chloroform), 에틸아세테이트(ethyl acetate), 메틸렌클로라이드(methylene chloride), 헥산(hexane) 및 시클로헥산(cyclohexane) 등의 각종 용매를 단독으로 혹은 혼합하여 사용할 수 있다. 추출방법으로는 열수추출법, 냉침추출법, 환류냉각추출법, 용매추출법, 수증기증류법, 초음파추출법, 용출법, 압착법 등의 방법 중 어느 하나를 선택하여 사용할 수 있다. 또한, 목적하는 혼합추출물은 추가로 통상의 분획 공정을 수행할 수도 있으며, 통상의 정제 방법을 이용하여 정제될 수도 있다. The mixed extract according to the present invention may be obtained by extracting and separating from nature using an extraction and separation method known in the art, and "mixed extract" as defined in the present invention uses an appropriate solvent. , It is extracted from gold and yellow lotus, for example, includes all of a crude extract, a polar solvent soluble extract or a non-polar solvent soluble extract. Any suitable solvent for extracting the mixed extract may be used as long as it is a pharmaceutically acceptable organic solvent, and water or an organic solvent may be used, but is not limited thereto, for example, purified water, methanol ), ethanol (ethanol), propanol (propanol), isopropanol (isopropanol), butanol (butanol), including alcohols having 1 to 4 carbon atoms, acetone (acetone), ether (ether), benzene (benzene), chloroform (chloroform) ), ethyl acetate, methylene chloride, hexane, and cyclohexane may be used alone or in combination. As the extraction method, any one of methods such as hot water extraction, cold precipitation extraction, reflux cooling extraction, solvent extraction, steam distillation, ultrasonic extraction, elution, compression, and the like can be used. In addition, the mixed extract of interest may be further subjected to a conventional fractionation process, or may be purified using a conventional purification method.
본 발명의 혼합추출물의 제조방법에는 제한이 없으며, 공지되어 있는 어떠한 방법도 이용될 수 있다. 예를 들면, 본 발명의 조성물에 포함되는 혼합추출물은 상기한 열수추출 또는 용매추출법으로 추출된 1차 추출물을, 감압 증류 및 동결 건조 또는 분무 건조 등과 같은 추가적인 과정에 의해 분말상태로 제조할 수 있다. 또한 상기 1차 추출물을 실리카겔 컬럼 크로마토그래피(silica gel column chromatography), 박층 크로마토그래피(thin layer chromatography), 고성능 액체 크로마토그래피(high performance liquid chromatography) 등과 같은 다양한 크로마토그래피를 이용하여 추가로 정제된 분획을 얻을 수도 있다. 따라서 본 발명에 있어서 인진, 계피, 황금 및 황련의 혼합추출물은 추출, 분획 또는 정제의 각 단계에서 얻어지는 모든 추출액, 분획 및 정제물, 그들의 희석액, 농축액 또는 건조물을 모두 포함하는 개념이다.There is no limitation on the method for preparing the mixed extract of the present invention, and any known method may be used. For example, the mixed extract included in the composition of the present invention may be prepared in a powder state by additional processes such as distillation under reduced pressure and freeze drying or spray drying of the primary extract extracted by the hot water extraction or solvent extraction method described above. . In addition, the primary extract was further purified using various chromatography such as silica gel column chromatography, thin layer chromatography, high performance liquid chromatography, etc. You can also get it. Therefore, in the present invention, the mixed extract of Injin, Cinnamon, Golden, and Coptis chinensis includes all extracts, fractions and purified products obtained in each step of extraction, fractionation, or purification, their dilutions, concentrates, or dried products.
본 발명에 사용된 혼합추출물은 주정(에탄올)을 추출용매로 하여 환류냉각추출법으로 추출하고, 이를 감압 농축 건조하여 수득한 것이나, 본 발명의 인진, 계피, 황금 및 황련의 혼합추출물의 유효성분을 추출하기 위한 추출용매 및 추출방법이라면, 이에 제한되지 않는다.The mixed extract used in the present invention was obtained by extracting alcohol (ethanol) by reflux cooling extraction using alcohol (ethanol) as an extraction solvent, and then concentrated and dried under reduced pressure, but the active ingredient of the mixed extract of injin, cinnamon, golden and yellow lotus If it is an extraction solvent and extraction method for extraction, it is not limited thereto.
본 발명에 따른 혼합추출물은 인진, 계피, 황금 및 황련을 (1~10):(1~10):(1~10):(1~10)의 중량비로 혼합하여 추출할 수 있고, 보다 바람직하게는 2:1:1:1의 중량비로 혼합하여 추출할 수 있다. 상기와 같이, 2:1:1:1의 중량비로 혼합하여 추출된 혼합추출물은 항염, 항알레르기, 항산화 및 피부 콜라겐 생성에 있어서 가장 우수한 효능을 나타내고, TNF-α 및 IgE의 발현량을 감소시키며, 타입 I 콜라겐 생성능을 증가시키는 바, 아토피 피부염 예방, 개선 내지 치료에 효과를 나타낼 수 있다.The mixed extract according to the present invention can be extracted by mixing injin, cinnamon, gold, and yellow lotus root in a weight ratio of (1-10):(1-10):(1-10):(1-10), more preferably It can be extracted by mixing in a weight ratio of 2:1:1:1. As described above, the mixed extract extracted by mixing at a weight ratio of 2:1:1:1 shows the best efficacy in anti-inflammatory, anti-allergic, antioxidant and skin collagen production, and reduces the expression levels of TNF-α and IgE. , By increasing the ability to produce type I collagen, it can be effective in preventing, improving or treating atopic dermatitis.
본 발명의 조성물이 약학 조성물인 경우, 투여를 위하여, 상기 기재한 유효성분 이외에 약학적으로 허용 가능한 담체, 부형제 또는 희석제를 포함할 수 있다. 상기 담체, 부형제 및 희석제로는 락토오스, 덱스트로오스, 수크로오스, 소르비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로오스, 메틸 셀룰로오스, 미정질 셀룰로오스, 폴리비닐피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.When the composition of the present invention is a pharmaceutical composition, for administration, it may include a pharmaceutically acceptable carrier, excipient, or diluent in addition to the above-described active ingredients. Examples of the carrier, excipient and diluent include lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum acacia, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, Polyvinylpyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, and mineral oils.
본 발명의 약학 조성물은 각각 통상의 방법에 따라 산제, 과립제, 정제, 캡슐제, 현탁액, 에멀젼, 시럽, 에어로졸 등의 경구형 제형, 외용제, 좌제 또는 멸균 주사용액의 형태로 제형화하여 사용할 수 있다. 상세하게는 제형화할 경우 통상 사용하는 충진제, 중량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다. 경구투여를 위한 고형 제제로는 정제, 환제, 산제, 과립제, 캡슐제 등을 포함하나, 이에 한정되는 것은 아니다. 이러한 고형 제제는 상기 유효성분 외에 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘 카보네이트, 수크로오스, 락토오스, 젤라틴 등을 섞어 조제될 수 있다. 또한, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 사용될 수 있다. 경구를 위한 액상물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등을 첨가하여 조제될 수 있다. 비경구 투여를 위한 제제는 멸균된 수용액, 비수성 용제, 현탁제, 유제, 동결건조 제제 및 과제를 포함한다. 비수성 용제 및 현탁제로는 프로필렌글리콜, 폴리에틸렌글리콜, 올리브 오일과 같은 식물성 오일, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔, 마크로솔, 트윈 61, 카카오지, 라우린지, 글리세로젤라틴 등이 사용될 수 있다.The pharmaceutical compositions of the present invention can be formulated and used in the form of oral dosage forms such as powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols, etc., external preparations, suppositories, or sterile injectable solutions according to a conventional method. . Specifically, when formulated, it may be prepared using diluents or excipients such as fillers, weight agents, binders, wetting agents, disintegrants, and surfactants that are commonly used. Solid preparations for oral administration include, but are not limited to, tablets, pills, powders, granules, capsules, and the like. Such a solid preparation may be prepared by mixing at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, gelatin, etc. in addition to the active ingredient. Further, in addition to simple excipients, lubricants such as magnesium stearate and talc may also be used. It can be prepared by adding various excipients, such as wetting agents, sweetening agents, fragrances, preservatives, and the like, in addition to oral liquids and liquid paraffin. Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized formulations, and tasks. As the non-aqueous solvent and suspending agent, propylene glycol, polyethylene glycol, vegetable oils such as olive oil, injectable esters such as ethyl oleate, and the like may be used. As a base for suppositories, witepsol, macrosol, Tween 61, cacao butter, laurin, glycerogelatin, and the like may be used.
본 발명의 약학 조성물의 적합한 투여량은 환자의 상태 및 체중, 질병의 정도, 약물형태, 시간에 따라 다르지만, 당 업자에 의해 적절하게 선택될 수 있는 바, 상기 조성물의 일일 투여량은 바람직하게는 0.001 mg/kg 내지 50 mg/kg이며, 필요에 따라 일일 1회 내지 수회로 나누어 투여할 수 있다.A suitable dosage of the pharmaceutical composition of the present invention varies depending on the condition and weight of the patient, the severity of the disease, the form of the drug, and the time, but may be appropriately selected by a person skilled in the art, and the daily dosage of the composition is preferably It is 0.001 mg/kg to 50 mg/kg, and it can be administered once to several times a day as needed.
또한, 본 발명은 인진(Artemisia capillaris), 계피(Cinnamomum cassia), 황금(Scutellaria baicalensis) 및 황련(Coptis japonica)의 혼합추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 개선용 화장료 조성물을 제공한다.In addition, the present invention provides a cosmetic composition for preventing or improving atopic dermatitis comprising a mixed extract of Injin (Artemisia capillaris), cinnamon (Cinnamomum cassia), Golden (Scutellaria baicalensis) and Coptis japonica as an active ingredient.
본 발명의 조성물이 화장료 조성물인 경우, 상기 화장료 조성물은 상기 유효성분 외에 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함할 수 있다. 또한, 상기 화장료 조성물은 그 효과를 증진시키기 위해 피부 흡수 촉진제를 추가로 포함할 수 있다.When the composition of the present invention is a cosmetic composition, the cosmetic composition may include conventional auxiliary agents such as stabilizers, solubilizers, vitamins, pigments and fragrances, and a carrier in addition to the active ingredients. In addition, the cosmetic composition may further include a skin absorption accelerator to enhance its effect.
상기 화장료 조성물의 제형은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 화장료 조성물은 화장수, 유액, 스킨, 토너, 로션, 에센스, 선 스크린, 크림, 메이크업 베이스, 파운데이션, 파우더, 팩, 젤, 연고, 패치, 스틱, 샴푸, 린스, 스프레이, 메이크업 제거제 및 세정제 등으로 제형화 될 수 있으나, 이에 한정되는 것은 아님을 명시한다.The formulation of the cosmetic composition may be prepared in any formulation conventionally prepared in the art, for example, the cosmetic composition is a lotion, emulsion, skin, toner, lotion, essence, sunscreen, cream, makeup base, foundation , Powder, pack, gel, ointment, patch, stick, shampoo, rinse, spray, makeup remover and detergent, etc. may be formulated, but is not limited thereto.
상기 제형이 페이스트, 크림 또는 겔인 경우에는 담체 성분으로서 동물성유, 식물성유, 왁스, 파라핀, 전분, 트라칸트, 셀룰로오스 유도체, 폴리에틸렌 글리콜, 실리콘, 벤토나이트, 실리카, 탈크 또는 산화아연 등이 이용될 수 있다.When the formulation is a paste, cream or gel, animal oil, vegetable oil, wax, paraffin, starch, tracant, cellulose derivatives, polyethylene glycol, silicone, bentonite, silica, talc, or zinc oxide may be used as a carrier component. .
상기 제형이 파우더 또는 스프레이인 경우에는 담체 성분으로서 락토스, 탈크, 실리카, 알루미늄 히드록시드, 칼슘 실리케이트 또는 폴리아미드 파우더가 이용될 수 있고, 특히 스프레이인 경우에는 추가적으로 클로로플루오로히드로카본, 프로판/부탄 또는 디메틸 에테르와 같은 추진체를 포함할 수 있다.When the formulation is a powder or spray, lactose, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component, and in particular, in the case of a spray, additional chlorofluorohydrocarbon, propane/butane Or a propellant such as dimethyl ether.
상기 제형이 용액 또는 유탁액인 경우에는 담체 성분으로서 용매, 용해화제 또는 유탁화제가 이용되고, 예컨대 물, 에탄올, 이소프로판올, 에틸 카보네이트, 에틸 아세테이트, 벤질 알코올, 벤질 벤조에이트, 프로필렌 글리콜, 1,3-부틸글리콜 오일, 글리세롤 지방족 에스테르, 폴리에틸렌 글리콜 또는 소르비탄의 지방산 에스테르가 있다.When the formulation is a solution or emulsion, a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, such as water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3 -Butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or fatty acid ester of sorbitan.
상기 제형이 현탁액인 경우에는 담체 성분으로서 물, 에탄올 또는 프로필렌 글리콜과 같은 액상의 희석제, 에톡실화 이소스테아릴 알코올, 폴리옥시에틸렌 소르비톨 에스테르 및 폴리옥시에틸렌 소르비탄 에스테르와 같은 현탁제, 미소결정성 셀룰로오스, 알루미늄 메타히드록시드, 벤토나이트, 아가 또는 트라칸트 등이 이용될 수 있다.When the above formulation is a suspension, a liquid diluent such as water, ethanol or propylene glycol as a carrier component, an ethoxylated isostearyl alcohol, a suspending agent such as polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, microcrystalline cellulose , Aluminum metahydroxide, bentonite, agar or tracant, and the like may be used.
또한, 본 발명은 인진(Artemisia capillaris), 계피(Cinnamomum cassia), 황금(Scutellaria baicalensis) 및 황련(Coptis japonica)의 혼합추출물을 유효성분으로 포함하는 아토피 피부염 예방 또는 개선용 건강식품 조성물을 제공한다.In addition, the present invention provides a health food composition for preventing or improving atopic dermatitis comprising a mixed extract of Injin (Artemisia capillaris), cinnamon (Cinnamomum cassia), Golden (Scutellaria baicalensis) and Coptis japonica as an active ingredient.
본 발명의 조성물이 건강식품 조성물인 경우, 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에 천연 과일 주스, 합성 과일 주스 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 또한, 건강식품 조성물은 육류, 소세지, 빵, 초콜릿, 캔디류, 스넥류, 과자류, 피자, 라면, 껌류, 아이스크림류, 스프, 음료수, 차, 기능수, 드링크제, 알코올 및 비타민 복합제 중 어느 하나의 형태일 수 있다.When the composition of the present invention is a health food composition, various nutrients, vitamins, minerals (electrolytes), flavoring agents such as synthetic flavoring agents and natural flavoring agents, coloring agents and thickening agents (cheese, chocolate, etc.), pectic acid and salts thereof , Alginic acid and salts thereof, organic acids, protective colloidal thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonates used in carbonated beverages, and the like. In addition, it may contain pulp for the manufacture of natural fruit juices, synthetic fruit juices and vegetable beverages. These components may be used independently or in combination. In addition, the health food composition may be in the form of any one of meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen, gum, ice cream, soup, beverage, tea, functional water, drink, alcohol and vitamin complex. I can.
또한, 상기 건강식품 조성물은 식품첨가물을 추가로 포함할 수 있으며, 식품첨가물로서의 적합 여부는 다른 규정이 없는 한 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반 시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정한다.In addition, the health food composition may additionally contain food additives, and the suitability as a food additive is determined according to the general rules and general test methods of the Food Additive Code approved by the Ministry of Food and Drug Safety, unless otherwise specified. It is judged according to standards and standards.
상기 식품첨가물공전에 수재된 품목으로 예를 들어, 케톤류, 글리신, 구연산 칼륨, 니코틴산, 계피산 등의 화학적 합성품, 감색소, 감초추출물, 결정셀룰로오스, 고랭색소, 구아검 등의 천연첨가물, L-글루타민산나트륨 제제, 면류 첨가 알칼리제, 보존료제제, 타르색소 제제 등의 혼합 제제류 등을 들 수 있다.For example, ketones, glycine, potassium citrate, nicotinic acid, chemical synthetic products such as cinnamic acid, dark pigment, licorice extract, crystalline cellulose, high cooling pigment, natural additives such as guar gum, L-glutamic acid And mixed preparations such as sodium preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations.
이때, 건강식품 조성물을 제조하는 과정에서 식품에 첨가되는 본 발명에 따른 조성물은 필요에 따라 그 함량을 적절히 가감할 수 있다.At this time, the composition according to the present invention added to the food in the process of manufacturing the health food composition can be appropriately added or subtracted, if necessary.
또한, 본 발명은 인진, 계피, 황금 및 황련을 (1~10):(1~10):(1~10):(1~10)의 중량비로 혼합하여 혼합물을 제조하는 제 1단계; 상기 혼합물에 물, 탄소수 1 내지 4의 알코올 또는 이의 혼합용액으로부터 선택된 용매를 첨가하고, 40 내지 80℃의 온도에서 3 내지 5시간 동안 추출물을 추출하는 제 2단계; 및 상기 추출물을 진공 농축시키고, 감압 농축하는 제 3단계;를 포함하는 혼합추출물의 제조방법을 제공한다.In addition, the present invention is a first step of preparing a mixture by mixing injin, cinnamon, gold and yellow lotus in a weight ratio of (1-10):(1-10):(1-10):(1-10); A second step of adding a solvent selected from water, alcohol having 1 to 4 carbon atoms, or a mixed solution thereof to the mixture, and extracting the extract for 3 to 5 hours at a temperature of 40 to 80°C; And a third step of vacuum concentrating the extract and concentrating under reduced pressure.
보다 바람직하게는, 상기 제 1단계는 인진, 계피, 황금 및 황련을 2:1:1:1의 중량비로 혼합할 수 있다. 상기 중량비로 혼합하여 추출된 혼합추출물은 항염, 항알레르기, 항산화 및 피부 콜라겐 생성에 있어서 가장 우수한 효능을 나타내고, TNF-α 및 IgE의 발현량을 감소시키며, 타입 I 콜라겐 생성능을 증가시키는 바, 아토피 피부염 예방, 개선 내지 치료에 효과를 나타낼 수 있다.More preferably, in the first step, injin, cinnamon, gold, and yellow lotus root may be mixed in a weight ratio of 2:1:1:1. The mixed extract extracted by mixing at the weight ratio shows the best efficacy in anti-inflammatory, anti-allergic, antioxidant and skin collagen production, reduces the expression levels of TNF-α and IgE, and increases the ability to produce type I collagen, atopy. It can be effective in preventing, improving or treating dermatitis.
상기 제 2단계는 초음파 추출기를 이용하여 추출될 수 있으나, 이에 제한되는 것은 아님을 명시한다.It should be noted that the second step may be extracted using an ultrasonic extractor, but is not limited thereto.
상기 제 3단계의 감압 농축은 25 내지 65℃의 수욕 및 1 내지 300 mbar의 압력에서 수행될 수 있으나, 이에 제한되는 것은 아님을 명시한다.The concentration under reduced pressure in the third step may be carried out in a water bath of 25 to 65° C. and a pressure of 1 to 300 mbar, but is not limited thereto.
상기 제조방법으로 제조된 혼합추출물은 항염, 항알레르기, 항산화 및 피부 콜라겐 생성에 있어서 우수한 효능을 나타내며, TNF-α 및 IgE의 발현량을 감소시키고, 타입 I 콜라겐 생성능을 증가시키는 바, 아토피 피부염 예방, 개선 내지 치료에 효과를 나타낼 수 있다.The mixed extract prepared by the above preparation method shows excellent efficacy in anti-inflammatory, anti-allergic, antioxidant and skin collagen production, reduces the expression levels of TNF-α and IgE, and increases the ability to produce type I collagen, preventing atopic dermatitis. , Improvement or treatment.
이하에서는 실시예를 통하여 본 발명을 더욱 상세히 설명하고자 한다. 이들 실시예는 오로지 본 발명을 보다 구체적으로 설명하기 위한 것으로, 본 발명의 요지에 따라 본 발명의 범위가 이들 실시예에 의해 제한되지 않는다는 것은 당업계에서 통상의 지식을 가진 자에 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for describing the present invention in more detail, and it will be apparent to those of ordinary skill in the art that the scope of the present invention is not limited by these examples according to the gist of the present invention. .
실험예 1: 인진, 계피, 황금 및 황련을 이용한 혼합추출물 제조 Experimental Example 1: Preparation of mixed extract using Injin, Cinnamon, Gold and Coptis
하기 표 1에 나타낸 바와 같이, 각 약재를 중량별로 혼합하여 실시예 1 내지 실시예 15의 혼합추출물을 제조하였다. 간략하게, 각 조건에 따라 각 약재를 중량 비율별로 혼합한 후, 70% 주정을 10 배수 첨가하고, 이후, 초음파 추출기를 이용하여 온도를 60℃로 유지하며 4시간 동안 추출을 수행하였다. 수득한 혼합추출물은 진공회전농축기(EYELA)를 이용하여 45℃의 수욕 및 200 mbar 이하의 압력에서 감압 농축하였으며, 최종적으로 각 조건의 혼합추출물을 수득하였다. As shown in Table 1 below, the mixed extracts of Examples 1 to 15 were prepared by mixing each medicine by weight. Briefly, after mixing each medicinal material by weight ratio according to each condition, 10 times 70% alcohol was added, and then, extraction was performed for 4 hours while maintaining the temperature at 60°C using an ultrasonic extractor. The obtained mixed extract was concentrated under reduced pressure in a water bath of 45° C. and a pressure of 200 mbar or less using a vacuum rotary concentrator (EYELA), and finally, a mixed extract of each condition was obtained.
실험예 2: 항염증 유효성 분석Experimental Example 2: Anti-inflammatory efficacy analysis
마우스 유래 대식세포주인 Raw264.7 세포를 이용하여 염증 유발 물질인 일산화질소(nitric oxide; NO)의 생성을 유도하고, 혼합추출물에 따른 일산화질소의 생성량을 측정하여 항염증 효능을 평가하였다. Raw264.7 cells, a mouse-derived macrophage cell line, were used to induce the production of nitric oxide (NO), a substance that induces inflammation, and the amount of nitrogen monoxide produced by the mixed extract was measured to evaluate the anti-inflammatory efficacy.
간략하게, Raw264.7 세포(한국세포주은행)는 10% 우태아혈청(fetal bovine serum; FBS)이 포함된 DMEM 배지를 이용하여 37℃, 5% CO2 배양기에서 배양하였다. 이후, 세포를 96 웰 플레이트에 4.3 X 104 세포/웰의 농도로 분주하고, 24시간 후 내독소로 작용하여 NO synthesis mitogen으로 사용되는 LPS(lipopolysaccharide)를 0.5 μg/mL 농도로 처리하였다. 37℃, 5% CO2 배양기에서 1시간 30분 동안 배양한 후, 각 시료를 100 μg/mL의 농도로 처리하고 24시간 동안 배양하였다. Briefly, Raw264.7 cells (Korea Cell Line Bank) were cultured in a DMEM medium containing 10% fetal bovine serum (FBS) in a 37°C, 5% CO 2 incubator. Thereafter, the cells were dispensed into a 96-well plate at a concentration of 4.3 X 10 4 cells/well, and after 24 hours, LPS (lipopolysaccharide) used as an NO synthesis mitogen was treated at a concentration of 0.5 μg/mL, acting as an endotoxin. After incubation for 1 hour and 30 minutes in a 37°C, 5% CO 2 incubator, each sample was treated at a concentration of 100 μg/mL and incubated for 24 hours.
다음으로 항염증 효능을 평가를 위해 NO assay를 수행하였다. 1M의 NaNO2를 표준곡선으로 0, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, 100 μM이 되도록 희석하여 기준값을 설정하였다. 다음으로, 1% 설파닐아마이드(sulfanilamide)와 0.1% N-1-나프틸에틸렌디아민[N-(1-naphthyl)ethylenediamine dihydrochloride] 시약을 1:1의 부피비로 혼합하고, 혼합 시약과 상기 Raw264.7 세포의 NO 생성 유도 실험에서 시료 처리 후 24시간 배양된 배지 상등액을 1:1의 부피비로 혼합하고(각 50 μL), 상온에서 10분간 반응시킨 다음 마이크로플레이트 리더기를 사용하여 540 nm에서 흡광도를 측정하여 대조군 대비 NO 생성 억제능을 분석하였다.Next, a NO assay was performed to evaluate the anti-inflammatory efficacy. 1M NaNO 2 was diluted to 0, 1.56 μM, 3.12 μM, 6.25 μM, 12.5 μM, 25 μM, 50 μM, and 100 μM as a standard curve to set the reference value. Next, 1% sulfanilamide and 0.1% N-1-naphthylethylenediamine [N-(1-naphthyl)ethylenediamine dihydrochloride] reagent were mixed in a volume ratio of 1:1, and the mixed reagent and the Raw264. 7 In the cell NO production induction experiment, the supernatant of the medium cultured for 24 hours after sample treatment was mixed in a volume ratio of 1:1 (50 μL each), reacted for 10 minutes at room temperature, and then absorbed at 540 nm using a microplate reader. By measuring, the ability to inhibit NO generation compared to the control was analyzed.
실험예 3: 항알레르기 유효성 분석Experimental Example 3: Anti-allergic efficacy analysis
항알레르기 유효성은 베타-헥소사미니다아제(β-hexosaminidase)의 양을 측정하여 평가하였다. 상기 베타-헥소사미니다아제 생성량의 억제는 면역세포의 탈과립화 방지 정도를 나타내는 지표이다.Anti-allergic efficacy was evaluated by measuring the amount of beta-hexosaminidase. The suppression of the production amount of beta-hexosaminidase is an index indicating the degree of prevention of degranulation of immune cells.
간략하게, 마우스 유래 염기성 비만세포주인 RBL-2H3 세포주(한국세포주은행)를 15% 우태아혈청(FBS), 100 unit/mL의 페니실린-스트렙토마이신이 포함된 MEM 배지를 이용하여 37℃, 5% CO2 배양기에서 배양하였다. 이후, 세포를 24 웰 플레이트에 2 X 105 세포/웰의 농도로 분주하여 24시간 동안 배양한 다음, 상등액을 제거하고 25 ng/mL의 anti-DNP IgE가 포함된 MEM 배지를 첨가하여 4시간 동안 배양하였다. 이후, 세포를 PIPES 완충액으로 2회 세척하고, 4 mM MgCl2, 5.6 mM 글루코스, 0.1% BSA가 포함된 PIPES 완충액으로 10분간 반응시켰다. 다음으로, 시료를 100 μg/mL의 농도로 20분 동안 처리한 후 50 ng/mL의 DNP-BSA를 넣고 20분 동안 반응시켰다. ice에서 10분 방치하여 반응을 종결시킨 후 상등액을 96 웰 플레이트로 옮기고, 1 mM P-니트로페닐-아세틸-β-D-글루코사미니드를 첨가하여 37℃에서 1시간 동안 반응시켰다. 다음으로, 정지액(stop solution; 0.1 M NaHCO3, 0.1 M Na2CO3)을 넣어 반응을 종결시킨 후 마이크로플레이트 리더기를 사용하여 405 nm에서 흡광도를 측정하였다. 양성대조군으로는 케토티펜(ketotifen, 100 μg/mL)을 사용하였다.Briefly, a mouse-derived basic mast cell line, RBL-2H3 cell line (Korea Cell Line Bank), was prepared using 15% fetal bovine serum (FBS) and 100 unit/mL of penicillin-streptomycin-containing MEM medium at 37°C, 5%. Incubated in a CO 2 incubator. Thereafter, the cells were dispensed into a 24-well plate at a concentration of 2 X 10 5 cells/well and cultured for 24 hours, and then the supernatant was removed and MEM medium containing 25 ng/mL anti-DNP IgE was added for 4 hours During incubation. Thereafter, the cells were washed twice with PIPES buffer, and reacted for 10 minutes with PIPES buffer containing 4 mM MgCl 2 , 5.6 mM glucose, and 0.1% BSA. Next, the sample was treated at a concentration of 100 μg/mL for 20 minutes, and then 50 ng/mL of DNP-BSA was added and reacted for 20 minutes. After the reaction was terminated by standing on ice for 10 minutes, the supernatant was transferred to a 96-well plate, and 1 mM P-nitrophenyl-acetyl-β-D-glucosamine was added to react at 37° C. for 1 hour. Next, a stop solution (0.1 M NaHCO 3 , 0.1 M Na 2 CO 3 ) was added to terminate the reaction, and the absorbance was measured at 405 nm using a microplate reader. As a positive control, ketotifen (100 μg/mL) was used.
실험예 4: 항산화 유효성 분석Experimental Example 4: Antioxidant effectiveness analysis
DPPH 라디칼 소거능에 대한 실험은 Blois의 방법을 변형하여 수행하였다. 간략하게, 각각의 희석한 시료 2 mL을 0.2 mM 1,1-diphenyl-2-picrylhydrazyl(DPPH) 2 mL과 혼합한 후 약 37℃에서 30분간 방치시킨 다음 마이크로플레이트 리더기를 사용하여 517 nm에서 흡광도를 측정하였다.The experiment on DPPH radical scavenging ability was performed by modifying the method of Blois. Briefly, 2 mL of each diluted sample was mixed with 2 mL of 0.2 mM 1,1-diphenyl-2-picrylhydrazyl (DPPH) and allowed to stand at about 37° C. for 30 minutes, and then absorbance at 517 nm using a microplate reader. Was measured.
실험예 2 내지 4에 대한 결과는 하기 표 2에 나타내었다. 표 2에 나타낸 바와 같이, 인진, 계피, 황금 및 황련의 2종 또는 3종의 혼합추출물(실시예 1 내지 10)에 비해 4종의 혼합추출물에서 항염증, 항알레르기 및 항산화 효능이 더 우수한 것을 확인하였다. 특히, 실시예 12에서 항염, 항알레르기 및 항산화 효능이 가장 우수한 것을 확인할 수 있었다. 이에, 실시예 1, 실시예 4, 실시예 8, 실시예 10, 내지 15를 이후 실험에 사용하였다. The results for Experimental Examples 2 to 4 are shown in Table 2 below. As shown in Table 2, it was found that the anti-inflammatory, anti-allergic, and antioxidant efficacy was better in the four mixed extracts compared to the two or three mixed extracts (Examples 1 to 10) of Injin, Cinnamon, Golden, and Coptis. Confirmed. In particular, it was confirmed that the anti-inflammatory, anti-allergic and antioxidant efficacy in Example 12 is the most excellent. Thus, Example 1, Example 4, Example 8, Examples 10, and 15 were used in subsequent experiments.
실험예 5: 항염증 사이토카인(TNF-α)의 발현량 분석Experimental Example 5: Analysis of the expression level of anti-inflammatory cytokine (TNF-α)
상기 실시예 1, 실시예 4, 실시예 8, 실시예 10 내지 15의 각 혼합추출물을 이용하여, 상기 혼합추출물이 TNF-α 발현량에 미치는 영향을 분석하였다. Using each of the mixed extracts of Examples 1, 4, 8, and 10 to 15, the effect of the mixed extract on the expression level of TNF-α was analyzed.
간략하게, Raw264.7 세포(한국세포주은행)를 6 웰 플레이트에 4 X 105 세포/웰 농도로 분주하고, 각 혼합추출물을 50, 100 및 200 μg/mL의 농도로 처리한 다음, 1시간 후에 LPS를 1 μg/mL 농도로 처리하였다. LPS 처리 후 12시간 후에 배지를 수거하였으며, 수거된 배지는 측정 전까지 -70℃에서 보관하였다. TNF-α의 발현량은 ELISA Kit(Pierce endogen, Rockford, IL, USA)를 사용하여 측정하였다.Briefly, Raw264.7 Cells (Korea Cell Line Bank) were dispensed into a 6-well plate at a concentration of 4 X 10 5 cells/well, and each mixed extract was treated at a concentration of 50, 100 and 200 μg/mL, and then 1 μg/LPS was added after 1 hour. Treated to mL concentration. The medium was collected 12 hours after LPS treatment, and the collected medium was stored at -70°C until measurement. The expression level of TNF-α was measured using an ELISA Kit (Pierce endogen, Rockford, IL, USA).
그 결과, 도 1에 나타낸 바와 같이, 200 μg/mL 농도에서 비교하였을 때, 2종의 약재를 혼합하여 추출한 혼합추출물의 경우 25~28%, 3종의 약재를 혼합하여 추출한 혼합추출물의 경우 27~31% TNF-α의 발현량이 억제되는 것을 확인하였다. 특히, 4종의 약재를 혼합하여 추출한 혼합추출물에서 TNF-α의 발현량이 39~43%로 가장 크게 억제되었으며, 그 중 실시예 12의 혼합추출물(인진:계피:황금:황련=2:1:1:1)이 43%로 가장 우수한 TNF-α의 발현 억제 효과를 나타내었다.As a result, as shown in FIG. 1, when compared at a concentration of 200 μg/mL, 25 to 28% of the mixed extract extracted by mixing two kinds of medicinal materials, and 27 in the case of the mixed extract extracted by mixing three kinds of medicinal materials. It was confirmed that the expression level of ~31% TNF-α was suppressed. In particular, the expression level of TNF-α in the mixed extract extracted by mixing 4 kinds of medicinal materials was the most suppressed at 39-43%, of which the mixed extract of Example 12 (Injin: Cinnamon: Golden: Hwangryeon = 2:1: 1:1) showed the best inhibitory effect on the expression of TNF-α at 43%.
실험예 6: IgE 발현량 분석Experimental Example 6: IgE expression level analysis
상기 실시예 1, 실시예 4, 실시예 8, 실시예 10 내지 15의 각 혼합추출물을 이용하여, 상기 혼합추출물이 IgE 발현량에 미치는 영향을 분석하였다. Using each of the mixed extracts of Examples 1, 4, 8, and 10 to 15, the effect of the mixed extract on the expression level of IgE was analyzed.
간략하게, IgE를 생산하는 인간 B 세포주인 U266B1 세포(림프모구종 세포) (American Type Culture Collection, Manassas, VA)를 24 웰 플레이트에 분주하고, RPMI-1640 배지(15% FBS, 2 mM L-글루타민, 10 mM HEPES, 1 mM 소듐 피루베이트, 50 μg 스트렙토마이신, 100 U/mL 페니실린 첨가)를 사용하여 37℃, 5% CO2 배양기에서 배양하였다. 세포를 2 X 105 세포/웰의 농도로 조정한 후, LPS를 2 μg/mL 농도로 처리하고, 각 혼합추출물을 각각 50, 100 및 200 μg/mL의 농도로 처리한 다음 7일 동안 배양하였다. 수거된 배지에서의 IgE 발현량은 ELISA Kit(PharMingen; San Diego, CA)를 사용하여 측정하였다.Briefly, U266B1 cells (lymphoblastoma cells), a human B cell line producing IgE (American Type Culture Collection, Manassas, VA), were dispensed into a 24-well plate, and RPMI-1640 medium (15% FBS, 2 mM L- Glutamine, 10 mM HEPES, 1 mM sodium pyruvate, 50 μg streptomycin, 100 U/mL penicillin added) was used to incubate in a 37°C, 5% CO 2 incubator. After adjusting the cells to a concentration of 2 X 10 5 cells/well, LPS was treated at a concentration of 2 μg/mL, and each mixed extract was treated at a concentration of 50, 100 and 200 μg/mL, respectively, and then incubated for 7 days. I did. The amount of IgE expression in the collected medium was measured using an ELISA Kit (PharMingen; San Diego, CA).
그 결과, 도 2에 나타낸 바와 같이, 모든 실험군에서 농도 의존적으로 IgE 발현량이 억제되는 것을 확인하였으며, 특히, 실시예 12의 혼합추출물이 가장 우수한 IgE의 발현 억제 효과를 나타내었다. As a result, as shown in FIG. 2, it was confirmed that the amount of IgE expression was suppressed in a concentration-dependent manner in all experimental groups, and in particular, the mixed extract of Example 12 showed the best effect of inhibiting the expression of IgE.
실시예 7: 콜라겐 생성능 분석Example 7: Analysis of collagen production ability
상기 실시예 1, 실시예 4, 실시예 8, 실시예 10 내지 15의 각 혼합추출물을 이용하여, 상기 혼합추출물이 type I 콜라겐 생성에 미치는 영향을 분석하였다. Using each of the mixed extracts of Examples 1, 4, 8, and 10 to 15, the effect of the mixed extract on the production of type I collagen was analyzed.
간략하게, 인간 유래 섬유아세포주(CCD-986SK 세포)를 48 웰 플레이트에 5 X 104 세포/웰 농도로 분주하고, 10% FBS가 포함된 DMEM 배지를 사용하여 37℃, 5% CO2 배양기에서 하룻밤 동안 배양하였다. 이후, 무혈청 DMEM 배지에서 24시간 배양한 각 혼합추출물을 50, 100 및 200 μg/mL의 농도로 처리하여 24시간 동안 배양한 다음 배지 상등액을 수거하였다. 양성대조군으로는 5 ng/mL의 TGF-β를 사용하였다. 수거된 배지에서의 콜라겐의 양은 ELISA Kit(Procollagen type I-peptide EIA kit, TAKARA, Lot No. AK3501)를 사용하여 측정하였다.Briefly, a human-derived fibroblast line (CCD-986SK cells) was dispensed into a 48-well plate at a concentration of 5 X 10 4 cells/well, and a DMEM medium containing 10% FBS was used in a 37° C., 5% CO 2 incubator. Incubated overnight. Then, each mixed extract cultured in serum-free DMEM medium for 24 hours was treated at concentrations of 50, 100 and 200 μg/mL, cultured for 24 hours, and then the medium supernatant was collected. As a positive control, 5 ng/mL of TGF-β was used. The amount of collagen in the collected medium was measured using an ELISA Kit (Procollagen type I-peptide EIA kit, TAKARA, Lot No. AK3501).
그 결과, 도 3에 나타낸 바와 같이, 모든 실험군에서 농도 의존적으로 콜라겐 생성능이 증가되는 것을 확인하였으며, 특히, 실시예 12의 혼합추출물이 가장 우수한 콜라겐 생성능을 나타내었다. As a result, as shown in FIG. 3, it was confirmed that the collagen production ability was increased in a concentration-dependent manner in all experimental groups, and in particular, the mixed extract of Example 12 showed the best collagen production ability.
상기 일련의 결과들을 통하여, 인진, 계피, 황금 및 황련 혼합추출물이 NO 생성을 억제하고, TNF-α 발현 감소와 같은 항염증 효능을 나타내는 것을 확인하였으며, 알레르기 반응에서 발생하는 베타-헥소사미니다제(탈과립의 지표) 및 IgE의 발현을 감소시켜 항알레르기 효능을 나타낼 뿐만 아니라, 항산화 효능 및 피부 콜라겐 생성에 영향을 주어 손상된 피부의 재생에 도움을 주는 것을 확인하였다. 이러한 효능은 2종 또는 3종의 혼합추출물에서 보다 4종의 혼합추출물에서 더 우수한 것을 확인할 수 있었고, 특히 실시예 12의 혼합추출물(인진:계피:황금:황련=2:1:1:1)에서 가장 우수한 효능을 나타내는 것을 확인하였다. Through the above series of results, it was confirmed that the mixed extract of Injin, Cinnamon, Golden, and Coptis chinensis inhibits NO production and exhibits anti-inflammatory effects such as decreased TNF-α expression, and beta-hexosaminidase occurring in allergic reactions It was confirmed that not only showed anti-allergic effect by reducing the expression of (indicator of degranulation) and IgE, but also aided in regeneration of damaged skin by affecting antioxidant effect and skin collagen production. This effect was found to be more excellent in 4 kinds of mixed extracts than in 2 kinds or 3 kinds of mixed extracts, especially the mixed extract of Example 12 (Injin: Cinnamon: Golden: Hwangryeon = 2:1:1:1) It was confirmed that the most excellent efficacy was shown.
이상으로 본 발명의 특정한 부분을 상세히 기술한 바, 당업계의 통상의 지식을 가진 자에게 있어서 이러한 구체적인 기술은 단지 바람직한 구현 예일 뿐이며, 이에 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 따라서, 본 발명의 실질적인 범위는 첨부된 청구항과 그의 등가물에 의하여 정의된다고 할 것이다.As the specific parts of the present invention have been described in detail above, it is obvious that these specific techniques are only preferred embodiments, and the scope of the present invention is not limited thereto for those of ordinary skill in the art. Therefore, it will be said that the substantial scope of the present invention is defined by the appended claims and their equivalents.
본 발명의 범위는 후술하는 특허청구범위에 의하여 나타내어지며, 특허청구범위의 의미 및 범위 그리고 그 균등 개념으로부터 도출되는 모든 변경 또는 변형된 형태가 본 발명의 범위에 포함되는 것으로 해석되어야 한다.The scope of the present invention is indicated by the claims to be described later, and all changes or modified forms derived from the meaning and scope of the claims and their equivalent concepts should be interpreted as being included in the scope of the present invention.
Claims (10)
상기 혼합물에 물, 탄소수 1 내지 4의 알코올 또는 이의 혼합용액으로부터 선택된 용매를 첨가하고, 40 내지 80℃의 온도에서 3 내지 5시간 동안 추출물을 추출하는 제 2단계; 및
상기 추출물을 진공 농축시키고, 감압 농축하는 제 3단계;를 포함하는 혼합추출물의 제조방법.A first step of preparing a mixture by mixing injin, cinnamon, gold and yellow lotus in a weight ratio of (1-10):(1-10):(1-10):(1-10);
A second step of adding a solvent selected from water, alcohol having 1 to 4 carbon atoms, or a mixed solution thereof to the mixture, and extracting the extract for 3 to 5 hours at a temperature of 40 to 80°C; And
A method for preparing a mixed extract comprising a third step of concentrating the extract in vacuo and concentrating under reduced pressure.
The method of claim 8, wherein the concentration under reduced pressure in the third step is performed in a water bath of 25 to 65°C and a pressure of 1 to 300 mbar.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190089035A KR102213593B1 (en) | 2019-07-23 | 2019-07-23 | Composition for preventing or treating atopic dermatitis comprising extracts of Artemisia capillaris, Cinnamomum cassia, Scutellaria baicalensis and Coptis japonica |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190089035A KR102213593B1 (en) | 2019-07-23 | 2019-07-23 | Composition for preventing or treating atopic dermatitis comprising extracts of Artemisia capillaris, Cinnamomum cassia, Scutellaria baicalensis and Coptis japonica |
Publications (2)
Publication Number | Publication Date |
---|---|
KR20210013380A true KR20210013380A (en) | 2021-02-04 |
KR102213593B1 KR102213593B1 (en) | 2021-02-15 |
Family
ID=74558556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190089035A KR102213593B1 (en) | 2019-07-23 | 2019-07-23 | Composition for preventing or treating atopic dermatitis comprising extracts of Artemisia capillaris, Cinnamomum cassia, Scutellaria baicalensis and Coptis japonica |
Country Status (1)
Country | Link |
---|---|
KR (1) | KR102213593B1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090127523A (en) * | 2008-06-09 | 2009-12-14 | 최양원 | Composition for treating atopy and acne |
KR20130077361A (en) * | 2011-12-29 | 2013-07-09 | 김태권 | A method of extraction of a medical plant for a skin ailment |
KR20170057213A (en) * | 2017-05-15 | 2017-05-24 | 경희대학교 산학협력단 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
KR20170108506A (en) * | 2016-03-18 | 2017-09-27 | (주)셀아이콘랩 | Composition comprising extracts of natural substance for alleviating itch or atopic dermatitis |
KR20190018108A (en) * | 2017-08-11 | 2019-02-21 | (주)에스디생명공학 | Composition Comprising Thymol for Preventing or Treating in Skin Wrinkle or Atopic Dermatitis as Active Ingredient |
KR20190074163A (en) | 2017-12-19 | 2019-06-27 | 주식회사 팩토리얼홀딩스 | Composition for treating atopy dermatitis comprising fermented product of Moringa by Rhizopus oligosporus and methods of preparation thererof |
-
2019
- 2019-07-23 KR KR1020190089035A patent/KR102213593B1/en active IP Right Grant
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20090127523A (en) * | 2008-06-09 | 2009-12-14 | 최양원 | Composition for treating atopy and acne |
KR20130077361A (en) * | 2011-12-29 | 2013-07-09 | 김태권 | A method of extraction of a medical plant for a skin ailment |
KR20170108506A (en) * | 2016-03-18 | 2017-09-27 | (주)셀아이콘랩 | Composition comprising extracts of natural substance for alleviating itch or atopic dermatitis |
KR20170057213A (en) * | 2017-05-15 | 2017-05-24 | 경희대학교 산학협력단 | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis |
KR20190018108A (en) * | 2017-08-11 | 2019-02-21 | (주)에스디생명공학 | Composition Comprising Thymol for Preventing or Treating in Skin Wrinkle or Atopic Dermatitis as Active Ingredient |
KR20190074163A (en) | 2017-12-19 | 2019-06-27 | 주식회사 팩토리얼홀딩스 | Composition for treating atopy dermatitis comprising fermented product of Moringa by Rhizopus oligosporus and methods of preparation thererof |
Non-Patent Citations (4)
Title |
---|
Cinnamomum cassia bark produced by solid-state fermentation with Phellinus baumii has the potential to alleviate atopic dermatitis-related symptoms, International Journal of Molecular Medicine,35,2015 * |
Effect of Artemisia capillaris Extracts on Antioxidant Activity and Allergic Dermatitis, Journal of Life Science 2012 Vol. 22. No. 7. 958~963 * |
Inhibitory effects of Cinnamomum cassia extract on atopic dermatitis-like skin lesions induced by mite antigen in NC/Nga mice, J Ethnopharmacol, 133(2), pp.621-8(2010.10.28.) * |
아토피(atopy) 관련 특허(생명연구자원 활용) 분석, 국가생명연구자원정보센터, KTR-20181130 * |
Also Published As
Publication number | Publication date |
---|---|
KR102213593B1 (en) | 2021-02-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Tang et al. | Review on research of the phytochemistry and pharmacological activities of Celosia argentea | |
JP6929954B2 (en) | Method for improving gingival inflammation and periodontitis by antibacterial, antioxidant, anti-inflammatory, suppression and regeneration of alveolar bone loss of Moringa leaf extract and Tochu extract complex | |
JP7471393B2 (en) | Tea composition having preventive or ameliorative effects on respiratory diseases and pharmaceutical composition containing the same | |
KR102422647B1 (en) | Composition for antioxidant and anti inflammation containing fermented product of Houttuynia cordata and scoria | |
KR101794567B1 (en) | The composition comprising the specific extract or the purified fraction isolated from Salvia pleia R. Br. as an active ingredient for preventing or treating respiratory inflammatory disease | |
KR20190090363A (en) | Cosmetic composition comprising mixture of fermented extract of Cirsium japonicum and Moringa oleifera | |
KR101794006B1 (en) | Anti inflammatory comprising plant extract | |
KR20120118188A (en) | Compostion for reducing irritation and inflammaion in skin comprising extracts of astragalus membranaceus | |
KR101944014B1 (en) | Antiobesitic composition comprising extract of Rhododendron mucronulatum | |
US20210113640A1 (en) | Composition for promoting hair growth or preventing hair loss containing extract of aster ageratoides | |
KR102197858B1 (en) | Composition for preventing or treating psoriasis comprising herb mixtures | |
KR102213593B1 (en) | Composition for preventing or treating atopic dermatitis comprising extracts of Artemisia capillaris, Cinnamomum cassia, Scutellaria baicalensis and Coptis japonica | |
KR20210141271A (en) | Composition for recylce a skin cell comprising of limonium tetragonum | |
KR102065470B1 (en) | Pharmaceutical composition containing rosae laevigatae with anti-allergy or anti-inflammatory activity and preparation method for the same | |
CN115887321A (en) | Hibiscus manihot extract with allergy relieving effect and application thereof | |
KR102535396B1 (en) | Composition for preventing or treating respiratory function damage caused by fine dust using citrus fruits peel and method for preparing the same | |
KR102007728B1 (en) | Composition for Preventing or Treating Allergy Diseases Comprising Extraction of Sasa borealis or its Fraction, and Reagent Composition Comprising the Same | |
KR100749675B1 (en) | Composition for immunosuppression comprising an extract of saururus chinensis or active compounds isolated therefrom | |
KR101337525B1 (en) | The Pharmaceutical compositions for prevention or treatment of hepatitis B containing extracts and fractions of Phyllanthus urinaria L and Hovenia dulcis Thunberg and Scutellaria baicalensis G. and Cinnamon as an active ingredient | |
KR102272637B1 (en) | Anti-inflammatory composition comprising Prunus pendula for. ascendens (Makino) Ohwi | |
KR101890220B1 (en) | Composition for preventing, improving and treating atopic dermatitis comprising ginseng berry extract fermented using Hericium erinaceum mycelium as effective component | |
KR102636204B1 (en) | Antiinflammatory or antiallergic composition comprising extract of Salvia chanryoenica | |
KR102297398B1 (en) | Composition for health food for improving of respiratory diseases caused by fine dust comprising extract of Liriope platyphylla, Glycyrrhiza uralensis and Aronia as an effective component | |
KR102184867B1 (en) | Pharmaceutical composition for preventing or treating atopic dermatitis comprising fraction of Pyrus ussuriensis extracts as an active ingredient | |
KR102617383B1 (en) | Anti-obesity composition using pomegranate, dioscorea rhizoma and polygonatum odratum extract as effective component and manufacturing method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AMND | Amendment | ||
E601 | Decision to refuse application | ||
X091 | Application refused [patent] | ||
AMND | Amendment | ||
X701 | Decision to grant (after re-examination) | ||
GRNT | Written decision to grant |